Recursion Pharmaceuticals
RXRX Small CapHealthcare · Biotechnology
Aktualisiert: Apr 5, 2026, 17:43 UTC
Kennzahlen
Bewertungs-Analyse
Über das Unternehmen
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1
Trading-Daten
Ähnliche Aktien aus dem Sektor
Wo kann ich Recursion Pharmaceuticals kaufen?
Vergleiche die besten Broker — niedrige Gebühren, seriöse Anbieter, reguliert.
